A class of chemotherapy drugs called anthracyclines, or anthracycline antibiotics, is commonly used in the treatment of breast cancer. These drugs will typically be combined with other kinds of chemotherapy medications to optimize response. Anthracyclines prevent cancer cells from growing causing cell death to occur. Common side effects of the anthracyclines include reddish urine for 1 to 2 days after treatment and possible heart damage if given at high doses. Before, during and after treatment with anthracyclines your heart function will be monitored closely to detect any changes.
Doxorubicin
Doxorubicin, generic for the brand name drug Adriamycin, is an anthracycline used in the treatment of breast cancer. It is typically given intravenously for approximately 15 minutes, with anti-nausea medicine commonly given prior to and after administration of the drug. Common side effects of doxorubicin include lowered white and red blood cell counts, which can lead to anemia and increased risk of infection, appetite loss, hair loss, nausea and vomiting, and skin changes.
Epirubicin
Epirubicin, also called Ellence, is used in the treatment of breast cancer. Side effects this medication might cause include lowered white and red blood cell counts, amenorrhea (cessation of menstrual periods), fatigue, mouth sores, nausea or vomiting, diarrhea and hair loss. It may also lower your platelet count, which interferes with your body's ability to clot blood.
Daunorubicin
Daunorubicin, also known as the brand name chemotherapy drug Daunomycin or Cerubidine, is another anthracycline that can be used to treat breast cancer. It is given intravenously, along with anti-nausea drugs similar to doxorubicin. Common side effects of daunorubicin include lowered white and platelet blood cell counts, nausea and vomiting, darkening of the fingernails and toenails and hair loss. This medication may increase uric acid levels in your body, which can cause kidney damage; to prevent this, your doctor will prescribe medicines or fluids if you are at risk.
